Affiliations: Department of Biotechnology, University of Kashmir, Srinagar, J&K, India
Correspondence:
[*]
Corresponding author: Raies Ahmad, Department of Biotechnology, University of Kashmir, J&K, 190006, India. Tel.: +91 941 900 1315; Fax: +91 194 242 8723; E-mail:raies@kashmiruniversity.ac.in
Abstract: Lung cancer is the major cause of cancer-related mortality worldwide owing
to its late-stage detection and aggressive behavior. Epidemiologically,
several genetic and epigenetic factors contribute to the development of lung
cancer. Angiogenesis, a critical process in tumor progression has become an
important target for anti-cancer therapy particularly in lung cancer.
Besides commercially available angiogenic inhibitors, numerous
anti-angiogenic therapies have been developed to limit tumor growth,
although, most of them have not proved beneficial in terms of long-term
survival. Despite, logical advances in treatment strategies, NSCLC still
remains a major health concern due to poor prognosis of the diseases state.
This calls for a comprehensive analysis of signaling processes governing
tumor angiogenesis and treatment options available thereof for development
of a sustainable strategy to control cancer. In this review, several aspects
of lung cancer have been discussed starting from its pathological
characterization to the development of modern therapeutics.
